Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ec-LDP(AE)-DF
- Development stage
- Preclinical
- Lead developer
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Ec-LDP(AE)-DF** is an experimental EGFR-targeted, enediyne-activated recombinant fusion protein developed as an antineoplastic candidate for non-small cell lung carcinoma. It comprises an EGF-derived EGFR-targeting oligopeptide, lidamycin apoprotein as a scaffold, a human beta-defensin-1-derived oncolytic peptide fragment, and the highly cytotoxic lidamycin enediyne chromophore. In preclinical NSCLC cell-line and A549/H460 xenograft studies, it bound EGFR-expressing tumor cells, produced exceptionally potent cytotoxicity, induced cell-cycle arrest and apoptosis, inhibited EGF-stimulated EGFR phosphorylation, and suppressed xenograft growth. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30206309/))
- Other names
- Ec-LDP (AE)-DF
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on Ec-LDP(AE)-DF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ec-LDP(AE)-DF.